HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dental Association Petitions FDA To Evaluate Tooth-Whitening Treatments

This article was originally published in The Rose Sheet

Executive Summary

The American Dental Association asks FDA to follow through on its promise to evaluate the safety of tooth-bleaching systems and classify the regulatory status of the products, which are rapidly increasing in number

You may also be interested in...



FDA Denies Petition To Classify Home Tooth Whiteners As Drugs

Data in a 2009 petition submitted by the American Dental Association is insufficient to warrant a drug designation for peroxide-containing tooth-whitening products as a group, according to the agency’s April 22 response. Further information on specific product formulations, mechanisms of action and safety profiles would be required for FDA to determine whether they meet the definition of a drug under federal law, the agency says.

P&G Defends Tooth-Whitening Cosmetic Classification In FDA Letter

Procter & Gamble urges FDA to deny a citizen petition by the American Dental Association to reclassify commercially available tooth whiteners as drugs, saying the petition is motivated by the financial interests of ADA members

P&G Defends Tooth-Whitening Cosmetic Classification In FDA Letter

Procter & Gamble urges FDA to deny a citizen petition by the American Dental Association to reclassify commercially available tooth whiteners as drugs, saying the petition is motivated by the financial interests of ADA members

Related Content

UsernamePublicRestriction

Register

RS016574

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel